Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
APX005M + Nivolumab + Cabiralizumab for Melanoma
Recruiting1 awardPhase 1
New Haven, Connecticut
This trial is a study to see if a new combination of drugs is safe and effective in treating advanced solid tumors. The study will enroll patients with melanoma, NSCLC, and RCC to see if the new combination is better than current treatments.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.